Chemotherapy: What Progress in the Last 5 Years?
Author:
Affiliation:
1. From the Sydney Cancer Centre and University of Sydney, Sydney, Australia; and The University of Texas M. D. Anderson Cancer Center, Houston TX
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.10.034
Reference149 articles.
1. Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
2. Jones S, Erban J, Overemoyer B, et al: Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 82:59,2004, (abstr 10; suppl 1).
3. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
4. Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over
Cited by 85 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bioconjugates: Preparation methods and therapeutic applications;Bioconjugated Materials Part 1 Preparation, Characterization and Applications in Therapeutics, Environmental monitoring and Point-of-care diagnostics;2023
2. 55. What would you do – a transnational study on veterinarians’ recommendations concerning radiotherapy in dogs and cats with cancer;Transforming food systems: ethics, innovation and responsibility;2022-09-01
3. Factors Which Influence Owners When Deciding to Use Chemotherapy in Terminally Ill Pets;Animals;2017-03-07
4. Contrast-Enhanced Computed Tomography Evaluation of Hepatic Metastases in Breast Cancer Patients before and after Cytotoxic Chemotherapy or Targeted Therapy;Canadian Association of Radiologists Journal;2015-11
5. Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment;Oncotarget;2015-04-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3